Abstract
Fungi are present in the mucus of chronic rhinosinusitis (CRS) patients and normal healthy controls. Fungi (especially Alternaria) induce the production of cytokines (IL-13 and IL-5) crucial for the eosinophilic inflammation. This immune response occurred only in CRS patients but not in healthy controls. Fungi induce an eosinophilic tissue airway inflammation in mammals (mice), which is in contrast to a neutrophilic response to bacteria. Fungi can induce an eosinophilic airway inflammation and congestion in patients. Eosinophils, in vivo, target fungi in the mucus with CRS and nasal polyps. Fungal antigens with a molecular weight of 61 kilodaltons (kDa) cause activation and degranulation of human eosinophils via the beta-2 integrin on the CD11b receptor. Clinically, antifungal drugs can reduce nasal polyps, improve computed tomography (CT) scans, and decrease levels of interleukin-5 (IL-5) and markers of eosinophilic inflammation. However, data between different antifungal applications and different outcome measures are conflicting.
| Original language | English (US) |
|---|---|
| Title of host publication | Nasal Polyposis: Pathogenesis, Medical and Surgical Treatment |
| Publisher | Springer Berlin Heidelberg |
| Pages | 95-101 |
| Number of pages | 7 |
| ISBN (Print) | 9783642114113 |
| DOIs | |
| State | Published - 2010 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Fungal-induced inflammation and nasal polyps. / Kern, Eugene B.; Sherris, David A.; Kita, Hirohito; Ponikau, Jens U.
Nasal Polyposis: Pathogenesis, Medical and Surgical Treatment. Springer Berlin Heidelberg, 2010. p. 95-101.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Fungal-induced inflammation and nasal polyps
AU - Kern, Eugene B.
AU - Sherris, David A.
AU - Kita, Hirohito
AU - Ponikau, Jens U.
PY - 2010
Y1 - 2010
N2 - Fungi are present in the mucus of chronic rhinosinusitis (CRS) patients and normal healthy controls. Fungi (especially Alternaria) induce the production of cytokines (IL-13 and IL-5) crucial for the eosinophilic inflammation. This immune response occurred only in CRS patients but not in healthy controls. Fungi induce an eosinophilic tissue airway inflammation in mammals (mice), which is in contrast to a neutrophilic response to bacteria. Fungi can induce an eosinophilic airway inflammation and congestion in patients. Eosinophils, in vivo, target fungi in the mucus with CRS and nasal polyps. Fungal antigens with a molecular weight of 61 kilodaltons (kDa) cause activation and degranulation of human eosinophils via the beta-2 integrin on the CD11b receptor. Clinically, antifungal drugs can reduce nasal polyps, improve computed tomography (CT) scans, and decrease levels of interleukin-5 (IL-5) and markers of eosinophilic inflammation. However, data between different antifungal applications and different outcome measures are conflicting.
AB - Fungi are present in the mucus of chronic rhinosinusitis (CRS) patients and normal healthy controls. Fungi (especially Alternaria) induce the production of cytokines (IL-13 and IL-5) crucial for the eosinophilic inflammation. This immune response occurred only in CRS patients but not in healthy controls. Fungi induce an eosinophilic tissue airway inflammation in mammals (mice), which is in contrast to a neutrophilic response to bacteria. Fungi can induce an eosinophilic airway inflammation and congestion in patients. Eosinophils, in vivo, target fungi in the mucus with CRS and nasal polyps. Fungal antigens with a molecular weight of 61 kilodaltons (kDa) cause activation and degranulation of human eosinophils via the beta-2 integrin on the CD11b receptor. Clinically, antifungal drugs can reduce nasal polyps, improve computed tomography (CT) scans, and decrease levels of interleukin-5 (IL-5) and markers of eosinophilic inflammation. However, data between different antifungal applications and different outcome measures are conflicting.
UR - http://www.scopus.com/inward/record.url?scp=84884486026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884486026&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-11412-0_11
DO - 10.1007/978-3-642-11412-0_11
M3 - Chapter
AN - SCOPUS:84884486026
SN - 9783642114113
SP - 95
EP - 101
BT - Nasal Polyposis: Pathogenesis, Medical and Surgical Treatment
PB - Springer Berlin Heidelberg
ER -